Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Cristina Gasparetto, MD, Michael Green, MD, Anandgopal Srinivasan, MDcal Student, Yubin Kang, MD, David A. Rizzieri, MD, Carlos Decastro, MD, Louis F. Diehl, MD, Anne Beaven, MD, Zighuo Li, PhD, Arati V. Rao, MD, Anderson Garrett, Sascha Tuchman, MD, Gwynn D. Long, MD

Blood (2015) 126 (23): 1857.

https://doi.org/10.1182/blood.V126.23.1857.1857

Published: 2015

Journal Articles

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Danielle M. Brander, MD, Anne W Beaven, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Cristina Gasparetto, MD, Thomas C. Shea, MD, Carlos deCastro, Joseph O. Moore, MD, David A. Rizzieri, MD

Blood (2012) 120 (21): 1626.

https://doi.org/10.1182/blood.V120.21.1626.1626

Published: 2012

Journal Articles

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Arati Rao, MD, David A. Rizzieri, MD, Eduardo Vanegas, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Donna Adams, RN, Julie Warzecho, RN, Carlos Decastro, MD

Blood (2012) 120 (21): 4948.

https://doi.org/10.1182/blood.V120.21.4948.4948

Published: 2012

Journal Articles

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

Arati Rao, MD, Ghazi Khan, David A. Rizzieri, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Anne W Beaven, MD, Donna Adams, RN, Julie Warzecho, RN, Carlos Decastro, MD

Blood (2012) 120 (21): 4935.

https://doi.org/10.1182/blood.V120.21.4935.4935

Published: 2012

Journal Articles

Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

Blood (2012) 120 (21): 414.

https://doi.org/10.1182/blood.V120.21.414.414

Published: 2012

Journal Articles

Feasibility Study of a Dose Dense Induction Regimen of High Dose Cytarabine (HiDAC) and Gemtuzumab Ozogamicin (Mylotarg™) for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia.

Arati V. Rao, MD, David A. Rizzieri, MD, Joseph O. Moore, MD, Carlos DeCastro, MD, Louis F. Diehl, MD, Amy P. Abernethy, MD, PhD, McLean Jordan, RN, Patty Davis, RN, Emily Edmonds, RN, Jon P. Gockerman, MD

Blood (2005) 106 (11): 4610.

https://doi.org/10.1182/blood.V106.11.4610.4610

Published: 2005

Journal Articles

Predictors of Survival in CLL: Multivariate Analyses Reveal Significant Correlation with IgV H Gene Mutation Status, Clinical Stage, and Cellular CD38 (but Not Zap-70) Expression.

Alicia D. Volkheimer, MS, Marc C. Levesque, MD, PhD, Bethany E. Beasley, BS, Louis Diehl, MD, Youwei Chen, MD, Gina Vaccaro, MD, Carlos DeCastro, MD, David Rizzieri, MD, Jon P. Gockerman, MD, Joseph O. Moore, MD, J. Brice Weinberg, MD

Blood (2005) 106 (11): 5010.

https://doi.org/10.1182/blood.V106.11.5010.5010

Published: 2005

Journal Articles

A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.

Cristina Gasparetto, MD, George P. Keogh, MD, Jon P. Gockerman, MD, Mitchell Horwitz, MD, Joseph O. Moore, MD, Carlos DeCastro, MD, Louis Diehl, MD, Patty Davis, RN, Nelson Chao, MD, David A. Rizzieri, MD

Blood (2005) 106 (11): 5181.

https://doi.org/10.1182/blood.V106.11.5181.5181

Published: 2005

Journal Articles

Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.

Sam O. Wanko, M.D, Jon P. Gocherman, M.D, Joseph O. Moore, M.D, Carlos Decastro, M.D, Robert Prosnitz, M.D, Cristina Gasparetto, M.D, John Chute, M.D, Mitchell Horowitz, M.D, Morris Ashley, Pharm.D, Edonds Emily, RN, Davis Patty, RN, Chao J. Nelson, M.D, David A. Rizzieri, M.D

Blood (2004) 104 (11): 1163.

https://doi.org/10.1182/blood.V104.11.1163.1163

Published: 2004

Journal Articles

Dose Dense, High Intensity Therapy in Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia Using Gemtuzumab Ozogamicin (Mylotarg™) and High Dose Cytarabine (HiDAC).

Arati V. Rao, M.D., David A. Rizzieri, M.D., Joseph O. Moore, M.D., Carlos DeCastro, M.D., Amy P. Abernethy, M.D., McLean Jordan, Patty Davis, Emily Edmonds, Jon P. Gockerman, M.D.

Blood (2004) 104 (11): 4516.

https://doi.org/10.1182/blood.V104.11.4516.4516

Published: 2004

Journal Articles

Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for Mantle Cell Lymphoma (MCL).

Liang-Piu Koh, MRCP, Jon P. Gockerman, MD, Joseph O. Moore, MD, Carlos DeCastro, MD, Gwynn D. Long, MD, Cristina Gasparetto, MD, Donna Niedzwiecki, PhD, Jon Edwards, MD, Leonard Prosnitz, MD, Mitchell Horwitz, MD, Jon Chute, MD, Ashley Morris, Pharm D, Martha Lassiter, Jennifer Loftis, Patty Davis, Nelson J. Chao, MD, David A. Rizzieri, MD

Blood (2004) 104 (11): 913.

https://doi.org/10.1182/blood.V104.11.913.913

Published: 2004

Journal Articles

Phase 1 trial study of 131 I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma

David A. Rizzieri, Gamal Akabani, Michael R. Zalutsky, R. Edward Coleman, Scott D. Metzler, James E. Bowsher, Bonnie Toaso, Elizabeth Anderson, Anand Lagoo, Steve Clayton, Charles N. Pegram, Joseph O. Moore, Jon P. Gockerman, Carlos DeCastro, Cristina Gasparetto, Nelson J. Chao, Darell D. Bigner

Blood (2004) 104 (3): 642–648.

https://doi.org/10.1182/blood-2003-12-4264

Published: 2004

Includes: Multimedia, Supplemental data

NARROW

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

Feasibility Study of a Dose Dense Induction Regimen of High Dose Cytarabine (HiDAC) and Gemtuzumab Ozogamicin (Mylotarg™) for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia.

Predictors of Survival in CLL: Multivariate Analyses Reveal Significant Correlation with IgV H Gene Mutation Status, Clinical Stage, and Cellular CD38 (but Not Zap-70) Expression.

A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.

Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.

Dose Dense, High Intensity Therapy in Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia Using Gemtuzumab Ozogamicin (Mylotarg™) and High Dose Cytarabine (HiDAC).

Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for Mantle Cell Lymphoma (MCL).

Phase 1 trial study of 131 I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only